DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $4.28 on Thursday. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.09. The firm has a market cap of $87.97 million, a price-to-earnings ratio of -0.95 and a beta of 0.71. The stock’s 50-day simple moving average is $4.22 and its 200-day simple moving average is $3.81.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.